Vir Biotechnology, Inc. (VIR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Vir Biotechnology, Inc. (VIR)
Go deeper and ask any question about VIR
Company Performance
Current Price
as of Sep 13, 2024$8.11
P/E Ratio
N/A
Market Cap
$1.11B
Description
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Metrics
Overview
- HQSan Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVIR
- Price$8.11+3.18%
Trading Information
- Market Cap$1.11B
- Float64.52%
- Average Daily Volume (1m)634,210
- Average Daily Volume (3m)951,116
- EPS-$3.58
Company
- Revenue$78.88M
- Rev Growth (1yr)-19.02%
- Net Income-$138.38M
- Gross Margin-40.23%
- EBITDA Margin-4,068.46%
- EBITDA-$125.10M
- EV$161.98M
- EV/Revenue2.05
- P/EN/A
- P/S14.01